The key overhang is Proposal 4 — if approved, the company can issue up to 1,236,668 shares upon exercise of warrants from the August 10 inducement, representing significant potential dilution (~114% of current shares outstanding). Monitor the subsequent 8-K for the final vote result on or after October 30, 2026.
Price Chart
Executive Summary
BIO-key International filed an 8-K reporting that at its reconvened 2026 Annual Meeting on October 2, 2026, stockholders approved the election of five director nominees, ratified the selection of M&K CPAs as auditor, and approved advisory say-on-pay compensation. The meeting was adjourned again to October 30, 2026 to allow more time for voting on Proposal 4, which seeks approval to issue up to 1,236,668 shares upon exercise of warrants from the August 10, 2026 warrant inducement transaction. The outcome of Proposal 4 remains pending and will be reported in a subsequent 8-K.
Key Facts
- Stockholders approved election of all five director nominees (Michael W. DePasquale, Wong Kwok Fong (Kelvin), Robert J. Michel, Emmanuel Alia, Cameron E. Williams).
- Ratification of M&K CPAs, PLLC as independent auditor for FY2026 was approved (497,275 for, 107,464 against, 2,039 abstentions).
- Advisory say-on-pay compensation was approved (175,347 for, 100,140 against, 2,910 abstentions, 328,381 broker non-votes).
- Annual Meeting was adjourned to October 30, 2026 to allow further voting on Proposal 4 (issuance of up to 1,236,668 shares upon warrant exercise).
- Proposal 4 relates to the August 10, 2026 warrant inducement transaction and requires stockholder approval under NASDAQ Listing Rule 5635(d).
- 606,778 shares (55.8% of 1,087,360 outstanding) were present, constituting a quorum.
Financial Impact
No financial impact from the approved proposals. Proposal 4, if passed, would allow issuance of up to 1,236,668 shares upon warrant exercise, representing ~114% dilution relative to the 1,087,360 shares outstanding as of the record date. Outcome is pending.
Risk Factors
- Potential approval of Proposal 4 would allow issuance of up to 1,236,668 shares, causing substantial dilution to existing shareholders.
- Adjournment signals difficulty securing sufficient votes for Proposal 4, which could indicate shareholder resistance to dilution.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032237 |
| Document: 0001437749-26-032237-index-headers.html | 0001437749-26-032237 |
| Document: 0001437749-26-032237-index.html | 0001437749-26-032237 |
| Document: 0001437749-26-032237.txt | 0001437749-26-032237 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | S-1 | $1.65 | awaiting T+60 | — | $2.86 (−73.03%) |
Oct 6, 2026 19d ago | DEFA14A | $1.76 | awaiting T+60 | — | $2.86 (+62.22%) |
Oct 6, 2026 19d ago | 8-K | $1.76 | awaiting T+60 | — | $2.86 (+62.22%) |
Oct 2, 2026 23d ago | 8-K | $1.93 | awaiting T+60 | — | $2.86 (−47.93%) |
Sep 29, 2026 27d ago | Press Release | $3.12 | awaiting T+60 | — | $2.86 (−8.49%) |
Aug 24, 2026 9w ago | DEFA14A | $2.97 | awaiting T+60 | — | $2.86 (+3.87%) |
Aug 14, 2026 10w ago | 8-K | $3.18 | awaiting T+60 | — | $2.86 (+10.22%) |
Aug 13, 2026 10w ago | Press Release | $3.18 | awaiting T+60 | — | $2.86 (−10.22%) |
Aug 10, 2026 11w ago | Press Release | $4.17 | awaiting T+60 | — | $2.86 (−31.53%) |
Jul 28, 2026 12w ago | Press Release | $4.25 $2.10 | ▼ −50.59% | ▼ −54.94% | $2.86 (−32.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers